title: Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Pediatric AIDS Clinical Trials Group.
abstract: A phase I dose-escalating safety and pharmacokinetic study evaluated an oral suspension of micronized atovaquone (m-atovaquone) in infants and children stratified into age groups from 1 month to 12 years of age. Dosages of 10, 30, and 45 mg/kg of body weight/day were evaluated as single daily doses over a period of 12 days. Steady-state concentrations in plasma were determined on day 12, and single postdose concentrations were measured on days 1, 3, 5, 7, 9, 13, 15, 18, 21, and 24. Prior studies with adults suggest that the average plasma atovaquone concentration of 15 micrograms/ml is associated with therapeutic success in more than 95% of patients with Pneumocystis carinii pneumonitis. The results showed m-atovaquone to be safe and well tolerated. Dosages of 30 mg/kg/day were adequate to achieve an average steady-state concentration of greater than 15 micrograms/ml in children ages 1 to 3 months and 2 to 12 years, but a dosage of 45 mg/kg/day was needed to reach this concentration in infants 3 to 24 months of age. The oral suspension of atovaquone is safe and well tolerated in children. A single daily dose of 30 mg/kg provides bioavailability considered adequate for therapy of P. carinii pneumonia, but infants between 3 and 24 months of age may require a dosage of 45 mg/kg/day.
authors.affiliation: St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. walter.hughes@stjude.org
authors.forename: W
authors.initials: W
authors.lastname: Hughes
authors.forename: A
authors.initials: A
authors.lastname: Dorenbaum
authors.forename: R
authors.initials: R
authors.lastname: Yogev
authors.forename: B
authors.initials: B
authors.lastname: Beauchamp
authors.forename: J
authors.initials: J
authors.lastname: Xu
authors.forename: J
authors.initials: J
authors.lastname: McNamara
authors.forename: J
authors.initials: J
authors.lastname: Moye
authors.forename: L
authors.initials: L
authors.lastname: Purdue
authors.forename: R
authors.initials: R
authors.lastname: van Dyke
authors.forename: M
authors.initials: M
authors.lastname: Rogers
authors.forename: B
authors.initials: B
authors.lastname: Sadler
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D053626:Atovaquone; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D009285:Naphthoquinones / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000378:metabolism
chemical_list: D000935:Antifungal Agents; D009285:Naphthoquinones; D053626:Atovaquone